We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.54B
AUM Growth
+$254M
Cap. Flow
+$211M
Cap. Flow %
13.67%
Top 10 Hldgs %
62.61%
Holding
55
New
12
Increased
18
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.4M
2
TGTX icon
TG Therapeutics
TGTX
+$28.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$28.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$26.8M
5
AZN icon
AstraZeneca
AZN
+$25.3M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$89.4M
2
TSRO
TESARO, Inc.
TSRO
+$25.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$18.3M
4
MDCO
Medicines Co
MDCO
+$13.1M
5
DBVT
DBV Technologies
DBVT
+$8.22M

Sector Composition

Rank Sector Weight
1 Healthcare 76.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$260M 16.83%
16,064,461
+1,325,000
+9% +$15.6M
BMRN icon
2
BioMarin Pharmaceuticals
BMRN
$11.9B
$106M 6.88%
1,189,524
+591,552
+99% +$51.4M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$105M 6.77%
7,263,122
+826,000
+13% +$11.3M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$80.3M 5.2%
4,398,101
+687,500
+19% +$10.7M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$75M 4.86%
1,102,884
+317,184
+40% +$22.2M
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
$72.5M 4.7%
1,841,896
+717,596
+64% +$26.8M
ARRY
7
DELISTED
Array Biopharma Inc
ARRY
$70M 4.54%
5,468,029
+115,000
+2% +$1.31M
ASND icon
8
Ascendis Pharma A/S
ASND
$16.7B
$67.3M 4.36%
1,681,024
+44,900
+3% +$1.63M
AVXS
9
DELISTED
AveXis, Inc. Common Stock
AVXS
$66M 4.28%
596,217
+159,515
+37% +$16M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$64.8M 4.2%
4,436,183
+920,083
+26% +$12.9M
ARGX icon
11
argenx
ARGX
$55.2B
$50.8M 3.29%
804,875
+375,275
+87% +$12.3M
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$50.6M 3.28%
1,263,313
+236,945
+23% +$9.1M
ASMB icon
13
Assembly Biosciences
ASMB
$507M
$48.4M 3.13%
89,045
+13,448
+18% +$6.09M
DERM
14
DELISTED
Dermira, Inc.
DERM
$42.3M 2.74%
1,520,000
– –
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.1B
$42M 2.72%
5,253,450
+1,052,107
+25% +$8.45M
PCRX icon
16
Pacira BioSciences
PCRX
$1.04B
$38.7M 2.51%
848,572
-462,888
-35% -$18.3M
MDCO
17
DELISTED
Medicines Co
MDCO
$35.4M 2.3%
1,296,560
-423,833
-25% -$13.1M
BMY icon
18
Bristol-Myers Squibb
BMY
$130B
$28M 1.81%
+456,223
New +$28.5M
TGTX icon
19
TG Therapeutics
TGTX
$8.38B
$27M 1.75%
+3,294,463
New +$28.8M
AZN icon
20
AstraZeneca
AZN
$270B
$26M 1.69%
+375,150
New +$25.3M
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$302M
$21.4M 1.39%
1,408,946
+420,676
+43% +$6.24M
TLGT
22
DELISTED
Teligent, Inc
TLGT
$18.3M 1.19%
504,943
+47,120
+10% +$2.25M
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$16.8M 1.09%
398,207
– –
CPRX
24
DELISTED
Catalyst Pharmaceutical
CPRX
$15.2M 0.99%
3,892,343
-743,402
-16% -$2.46M
INDP icon
25
Indaptus Therapeutics
INDP
$264M
$11.3M 0.73%
980
– –
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Avoro Capital Advisors held 55 positions worth $1.54B, up 20% from $1.29B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Avoro Capital Advisors deployed $211M of net new capital in Q4 2017, opening 12 new positions and adding to 18 existing holdings. Its largest new stake was TG Therapeutics: 3,294,463 shares worth $27M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 67% a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $18.3M trimmed.

  • Avoro Capital Advisors's largest Q4 2017 buy was TG Therapeutics: 3,294,463 shares worth $27M.
  • Avoro Capital Advisors added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $51.4M increase.
  • Avoro Capital Advisors's biggest Q4 2017 reduction was Pacira BioSciences, cutting an estimated $18.3M.
  • Avoro Capital Advisors fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $89.4M.
  • Avoro Capital Advisors's ten largest holdings make up 63% of its $1.54B portfolio in Q4 2017.
  • Avoro Capital Advisors opened 12 new positions and closed 5 in Q4 2017.
  • Avoro Capital Advisors's portfolio value rose 20% quarter-over-quarter to $1.54B.

Based on Avoro Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.